Moxibustion combined with herbs for the prophylactic and therapeutic use of joint pain caused by aromatase inhibitors in postmenopausalbreast cancer: a randomized controlled trial

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of TCM0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. All patients were meet the pattern identification criteria of TCM and diagnostic criteria of western medicine;
•2. Patients must be postmenopausal female;
•3. Aged from 45 to 75 years;
•4. Pathological investigations confirmed a primary invasive breast cancer;
•5. According to the pathological results and the physical condition, all patients were required to take AI with breast cancer guidelines of CBCSG (version 2019);
•6. Patients who have taken AI for at least three months ;
•7. Patients who have joint pains during taking AI and the score about BPI-SF > 4;
•8. Be willing to participate in clinical trials and be able to cooperate with regular follow-up;
•9. All patients must have signed and dated an informed consent form.

•1. Recurrent and metastatic breast cancer;
•2. Severe liver and kidney dysfunction (AST/SGOT or ALT/AGPT is > 2.5 times of the ULN, and Serum Cr is >= 150umol/L);
•3. Severe heart dysfunction other organ failure;
•4. Any previous or concurrent primary malignancy;
•5. A history of fracture or joint surgery within 6 months;
•6. Patients who had used traditional Chinese medicine, moxibustion treatment or other TCM related treatment for AIA in the past 3 months;
•7. Participating in other clinical trials within 3 months;
•8. In any reason that cannot cooperate with the study, such as language understanding, unable to refer to the research center, etc.;
•9. Other conditions or diseases that may be excluded from the study that may result in significant risk or confusion in the study;
•10. Previous use of NSAIDs and opioid analgesics.

发起方

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of TCM